Kolon Biotech to Participate in 'BIO KOREA 2026' to Showcase CDMO Capabilities

Kolon Biotech, a subsidiary of Kolon Life Science, announced on the 24th that it will participate in 'BIO KOREA 2026,' held from April 28 to 30 at COEX in Samseong-dong, Gangnam-gu, Seoul, to explore new client companies and expand cooperation opportunities.

During the event, Kolon Biotech will operate an independent booth, highlighting its expertise as a Contract Development and Manufacturing Organization (CDMO). The company plans to strengthen connections with client companies by showcasing its 'end-to-end service' capabilities, covering the entire cycle from early-stage development through clinical trials to commercial production.

Kolon Biotech, a subsidiary of Kolon Life Science, will participate in "BIO KOREA 2026," held from the 28th to the 30th of this month at COEX in Samseong-dong, Gangnam-gu, Seoul, to discover new clients and expand cooperation opportunities. Kolon Biotech

The core focus of this booth is 'customized services for each clinical stage.' For companies in the early clinical phase, Kolon Biotech offers scalable process development and optimized Good Manufacturing Practice (GMP) services, leveraging its experience in commercial supply. For those in the late clinical and commercialization stages, the company proposes its '2D Automated Closed Platform' technology, which is characterized by supporting high-quality and high-yield production while minimizing the risk of contamination.

The company is also seeking to establish mid- to long-term partnerships with domestic and international biotech firms that have outstanding pipelines. At the initial stage, Kolon Biotech will lower the client’s burden by providing samples at reasonable costs, and later, expand the scope of cooperation to clinical and commercial production, laying a foundation for mutual growth.

Kolon Biotech possesses over 20 years of manufacturing experience and a robust GMP infrastructure in advanced biopharmaceutical fields such as cell therapy, gene therapy, and exosome therapy. The company provides integrated services that span the entire biopharmaceutical production process—from cell banking, which forms the basis of drug development, to large-scale process development and manufacturing of both raw materials and finished pharmaceutical products.

Its credibility in the global market has also been verified. Kolon Biotech has experience in producing more than 100 commercial batches and holds numerous records of submitting Investigational New Drug (IND) applications to the Ministry of Food and Drug Safety (MFDS) and the U.S. Food and Drug Administration (FDA). The company is also building a large-scale production process for the commercialization in the United States of 'TG-C,' a knee osteoarthritis treatment currently being developed by Kolon TissueGene. Through these efforts, Kolon Biotech is actively supporting Asian biotech companies in their entry into the U.S. and Japanese markets.

Beom-yong Oh, CEO of Kolon Biotech, stated, "Kolon Biotech has built unrivaled capabilities by carrying out a variety of projects in the CDMO field," adding, "At BIO KOREA 2026, we will introduce differentiated production solutions and become the optimal partner for our client companies."

This content was produced with the assistance of AI translation services.